Skip to main content

Table 3 Adoptive cell therapy (ACT) clinical trials using CRISPR/Cas9 technology for the treatment of cancer. Data extracted from https://clinicaltrials.gov/ (last accessed 6/3/2021)

From: CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy

Clinical Trial Number Delivery Method Phase Target Gene/ Purpose Cancer Type Cell Type Sponsor/Country Date Posted/ Last Update Recruitment Status
NCT02793856 N/A I PDCD1-KO Metastatic Non-small Cell Lung Cancer Primary T-cells Peking University/China 6/8/2016
1/12/2021
Completed
NCT02863913 N/A I PDCD1-KO Stage IV Invasive Bladder Cancer Primary T-cells Peking University/China 8/11/2016
3/6/2019
Withdrawn
NCT02867332 N/A I PDCD1-KO Metastatic Renal Cell Carcinoma Primary T-cells Peking University/China 8/15/2016
3/6/2019
Withdrawn
NCT02867345 N/A I PDCD1-KO Hormone Refractory Prostate Cancer Primary T-cells Peking University/China 8/15/2016
3/6/2019
Withdrawn
NCT03044743 N/A I/II PDCD1-KO Multiple Neoplasms Ant-EBV CTLs The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School/China 2/7/2017
5/2/2017
Recruiting
NCT03081715 N/A I PDCD1-KO Esophageal Cancer Primary T-cells Hangzhou Cancer Center/China 3/16/2017
6/12/2019
Completed
NCT03538613 N/A I/II CISH-KO Metastatic Gastrointestinal Cancers TILs National Cancer Institute/USA 6/11/2020
6/16/2020
Recruiting
NCT04089891 N/A I/II CISH-KO Metastatic Gastrointestinal Epithelial Cancer TILs Masonic Cancer Center, University of Minnesota/USA 10/31/2019
8/3/2020
No Longer Active
NCT03398967 N/A I/II TRAC, CD52-KO B cell Lymphoma/Leukemia CD19/20- or CD19/22- UCART Chinese PLA General Hospital/China 1/16/2018
1/16/2018
Recruiting
NCT03166878 Lentiviral (CAR)
Electroporation (TCR/B2M)
I/II TRAC, TRBC, B2M-KO B cell Lymphoma/Leukemia CD19-UCART Chinese PLA General Hospital/China 5/25/2017
6/23/2017
Recruiting
NCT03690011 N/A I CD7-KO T-cell Malignancies CD7-CAR T-cells Baylor College of Medicine/USA 10/1/2018
3/26/2021
Not yet recruiting
NCT03747965 N/A I PDCD1-KO Multiple Mesothelin Positive Solid Tumors Anti-mesothelin UCART Chinese PLA General Hospital/China 11/20/2018 Unknown
NCT03545815 N/A I TRAC, PDCD1-KO Multiple Mesothelin Positive Solid Tumors Anti-mesothelin UCART Chinese PLA General Hospital/China 6/4/2018
8/10/2020
Recruiting
NCT04035434 Electroporation I TRAC-KO B cell Lymphoma/Leukemia CD19-UCART (CTX110) CRISPR Therapeutics AG/USA 7/29/2019
1/19/2021
Recruiting
NCT04037566 Lentiviral (CAR)
Electroporation (HPK1)
I HPK1-KO B cell Lymphoma/Leukemia CD19-CAR T-cells Xijing Hospital/China 7/30/2019
7/30/2019
Recruiting
NCT03399448 Electroporation I TRAC, TRBC, PDCD1-KO Multiple Malignancies NYCE T cells University of Pennsylvania/USA 1/16/2018
10/12/2020
Terminated